Showing 4431-4440 of 9116 results for "".
- YCANTH Receives Permanent J-Code Status from CMShttps://practicaldermatology.com/news/ycanth-receives-permanent-j-code-from-cms/2462230/The Centers for Medicare and Medicaid Services (CMS) have granted a permanent J-code (J7354) for YCANTH, the only FDA-approved treatment for molluscum contagiosum.
- Benzoyl Peroxide 2.6% Cleanser Effective at Reducing Acne Lesionshttps://practicaldermatology.com/news/benzoyl-peroxide-26-cleanser-effective-at-reducing-acne-lesions/2462228/A benzoyl peroxide 2.6% (BPO) complexion clearing acne cleanser (CCAC) was effective at reducing acne, a new study reports.
- Study Reveals TikTok's Impact on Psoriasis Treatment Understandinghttps://practicaldermatology.com/news/study-reveals-tiktoks-impact-on-psoriasis-treatment-understanding/2462223/A new study published in the Journal of Drugs in Dermatology offers a glimp
- Guselkumab Demonstrates Significant and Rapid Scalp Psoriasis Clearance in People of Colorhttps://practicaldermatology.com/news/tremfya-guselkumab-demonstrates-significant-and-rapid-scalp-psoriasis-clearance-in-people-of-color-in-new-large-phase-3b-study/2462218/At the Maui Derm Hawaii 2024 conference, Johnson & Johnson presented topline data from Cohort B in the Phase 3b VISIBLE study that demonstrated that TREMFYA® (guselkumab) showed rapid and significant clearance in moderate to severe scalp psoriasis (PsO) and significant improvement
- Bimekizumab Shown Safe at 3 Years for Moderate-to-Severe Plaque Psoriasishttps://practicaldermatology.com/news/bimekizumab-shown-safe-at-3-years-for-moderate-to-severe-plaque-psoriasis/2462216/In a poster presented at Maui Derm, 2024, results from a long-term pooled analysis from five phase-3/3b trials indicate that bimekizumab (BKZ) is safe and well-tolerated at the 3-year mark in patients with moderate-to-s
- Analysis: Women, Minorities Underrepresented in Psoriasis Researchhttps://practicaldermatology.com/news/analysis-women-minorities-underrepresented-in-psoriasis-research/2462215/A new analysis suggested that women and minorities are consistently underrepresented in the psoriasis and hidradenitis suppurativa (HS) medical literature. "Ensuring clinical trial populations reflect the racial, ethnic, and sex makeup of patient populations is important for
- New Assessment Tool for Chronic Prurigo Shows Power of Patient Reportinghttps://practicaldermatology.com/news/development-and-validation-of-a-patient-reported-outcome-measure-to-assess-disease-control-in-chronic-prurigo/2462214/Researchers have introduced a 5-item Prurigo Control Test (PCT), in what could be the first patient-reported outcome measure for determining disease control for chronic prurigo (CPG). This tool, according to the researchers, was designed to assess disease control in CPG
- Upadacitinib in Atopic Dermatitis: New Safety Data Encourages Practitioners and Patientshttps://practicaldermatology.com/news/long-term-safety-of-upadacitinib-in-atopic-dermatitis-5-year-analysis-unveils-encouraging-results/2462210/A recent analysis reveals that upadacitinib, an oral Janus kinase 1 (JAK1) inhibitor, maintains its safety profile over a span of 5 years, aiding individuals
- FDA Deems Vaporized Hydrogen Peroxide an Established Method of Sterilizationhttps://practicaldermatology.com/news/fda-deems-vaporized-hydrogen-peroxide-an-established-method-of-sterilization/2462205/The U.S. Food and Drug Administration (FDA) announced that it now considers vaporized hydrogen peroxide (VHP) as an established method of sterilization for medical devices. In what the agency called a recognition of its long-time effectiveness, it revised the final guidance on the
- Upadacitinib Linked with Improvement for Hand Eczema in Patients with Atopic Dermatitishttps://practicaldermatology.com/news/updacitinib-shows-promise-for-ad-and-hand-eczema-in-trial/2462198/Results from a new study suggest that upadacitinib is efficacious for the treatment of hand eczema (HE) and atopic dermatitis (AD) in patients with AD. The study authors, publishing in Contact Dermatitis, included a total of 38 patients in the observational cohort analysis (32 of